Energy Balance in Advanced Breast Cancer: Extending Beyond the Curative Setting

Abstract: Outcomes in early-stage breast cancer, including quality of life, body composition, physical functioning, physiologic biomarkers, cancer recurrence, and mortality, are associated with body weight, diet, […]

The Effectiveness of Immune Checkpoint Inhibitors in the Neoadjuvant and Post-Neoadjuvant Breast Cancer Settings

H&O  Could you describe the design of the KEYNOTE-522 study?  LP  KEYNOTE-522 was a large, randomized, placebo-controlled phase 3 trial that tested pembrolizumab (Keytruda, Merck) as […]

Highlights in Breast Cancer From the 2022 American Society of Clinical Oncology Annual Meeting

June 2-6, 2022 • Chicago, Illinois Trastuzumab Deruxtecan Improves Survival in HER2-Low Metastatic Breast Cancer The antibody-drug conjugate (ADC) trastuzumab deruxtecan, also known as T-DXd (Enhertu, […]

Managing Adverse Events of Immunotherapy in Breast Cancer

H&O  Which immunotherapy agents have been approved for use in breast cancer?  HS  The first immunotherapy agent to receive accelerated approval for breast cancer in the […]

The Use of Immunotherapy in Triple-Negative Breast Cancer

H&O  Which patients with triple-negative breast cancer (TNBC) are eligible for immunotherapy?  PS  We generally use immunotherapy in TNBC for 2 indications. One indication is the […]

New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer

H&O  What data led the US Food and Drug Administration (FDA) to approve sacituzumab govitecan-hziy? AB  The antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy, Gilead) targets the human […]

The Use of Neoadjuvant Therapy to Further Personalize Breast Cancer Treatment

H&O  What are the goals of neoadjuvant treatment in breast cancer? LE  The most important goal is to find out which medicines are effective at reducing […]

New Targets in Endocrine-Resistant Hormone Receptor–Positive Breast Cancer

Abstract: Endocrine-based treatments are the backbone of initial therapy for advanced hormone receptor–positive breast cancers. Developing new therapeutic strategies to address resistance to endocrine therapy is […]

The Evolving Use of SERDs in Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

H&O What is the mechanism of action of selective estrogen receptor degraders (SERDs)? RJ  SERDs are direct estrogen receptor antagonists that lead to destabilization and degradation […]

The Optimal Duration of Endocrine Therapy in Hormone Receptor–Positive Breast Cancer

H&O  Which patients are eligible for endocrine therapy alone vs endocrine therapy plus chemotherapy? GS  Historically, we based this decision on the TNM (tumor, node, metastasis) […]

The Evolving Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer

Abstract: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer for which chemotherapy had been the only active treatment option once metastatic disease developed. […]

Update on Antibody-Drug Conjugates in Breast Cancer

H&O  How do antibody-drug conjugates (ADCs) work? HR  These anticancer drugs have a fascinating construct that combines an antibody, a toxin, and a linker. The idea […]

Circulating Tumor DNA in Early-Stage Breast Cancer: New Directions and Potential Clinical Applications

Abstract: The use of circulating tumor DNA (ctDNA) in liquid biopsy as a biomarker is becoming the new paradigm for the screening and surveillance of breast […]

HER2-Positive Metastatic Breast Cancer: A Comprehensive Review

Abstract: Cases of human epidermal growth factor receptor 2 (HER2)–positive breast cancer represent approximately 15% to 20% of all breast cancers. Historically, this subtype of breast […]

Novel Therapies for Triple-Negative Breast Cancer

H&O  How common is triple-negative breast cancer? RN  Triple-negative breast cancer (TNBC) is less common than other forms of breast cancer, accounting for approximately 15% of […]

A Closer Look at Sacituzumab Govitecan-hziy

  Sacituzumab govitecan-hziy (Trodelvy, Immunomedics) is an antibody-drug conjugate indicated for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least […]

Intratumoral HER2 Heterogeneity in Breast Cancer

  H&O  How is intratumoral HER2 heterogeneity defined? MP  No general consensus exists regarding the definition of human epidermal growth factor receptor 2 (HER2) heterogeneity. That […]

Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer

Abstract: The management of early-stage human epidermal growth factor receptor 2–positive (HER2+) breast cancer has evolved in recent years, with the current standard being to tailor […]

Highlights From the 2019 San Antonio Breast Cancer Symposium

  Tucatinib Improves Survival in Metastatic HER2-Positive Breast Cancer The addition of tucatinib to trastuzumab and capecitabine improved progression-free survival (PFS) and overall survival (OS) in […]

Treatment of Early-Stage Hormone Receptor–Positive Breast Cancer

H&O  What are the most important questions for oncologists treating patients with early-stage hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer after surgery? HR  […]